Werewolf Therapeutics, Inc. (HOWL)
HOWL moved a median of -1.06% 30 minutes after news, and -2.55% by the close. How HOWL actually reacts to news — the realized, point-in-time move the market made, measured across 345 labeled events over the last three years with zero look-ahead.
HOWL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 37% | 345 |
| 30-min | -1.06% | 26% | 345 |
| 60-min | -1.56% | 27% | 345 |
| to close | -2.55% | 32% | 342 |
| Middle 50% of HOWL reactions | -3.08% to +0.25% |
|---|---|
| Median reaction (30-min) | -1.06% |
| Measured reactions | 345 |
Half of all Werewolf Therapeutics, Inc. news events land between -3.08% and +0.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when HOWL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HOWL's baseline. Nothing else.
Recent HOWL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX) | Press release | GlobeNewswire | +0.32% | -0.43% | |
| Form S-4 Werewolf Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | +1.18% | +1.59% | |
| Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.21% | -0.97% | |
| Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | +2.80% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ) | Press release | GlobeNewswire | -0.21% | -0.30% | |
| HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -2.65% | +3.92% | |
| Form 8-K Werewolf Therapeutics, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | -10.87% | |
| Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement | Press release | GlobeNewswire | +3.07% | -10.87% | |
| Form 8-K Werewolf Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | -10.87% | |
| Form 10-Q Werewolf Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.06% | -29.38% | |
| Form 8-K Werewolf Therapeutics, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -6.06% | -29.38% | |
| Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates | Press release | GlobeNewswire | -6.06% | -29.38% | |
| Form 10-Q Werewolf Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +9.85% | +9.98% | |
| Form 8-K Werewolf Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +9.85% | +9.98% | |
| Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates | Press release | GlobeNewswire | +9.85% | +9.98% | |
| Form 10-K Werewolf Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.71% | -7.05% | |
| Form 8-K Werewolf Therapeutics, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -0.71% | -7.05% | |
| Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates | Press release | GlobeNewswire | -0.71% | -7.05% | |
| Form 8-K Werewolf Therapeutics, For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +6.25% | +0.00% | |
| Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives | Press release | GlobeNewswire | +6.25% | +0.00% | |
| Form 8-K Werewolf Therapeutics, For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | -0.20% | |
| Form 8-K Werewolf Therapeutics, For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | -1.98% | +7.13% | |
| Form 8-K Werewolf Therapeutics, For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -18.12% | -19.18% | |
| Werewolf Therapeutics Announces Pipeline and Business Updates | Press release | GlobeNewswire | -18.12% | -19.18% | |
| Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting | Press release | GlobeNewswire | -1.67% | -2.54% | |
| Form 10-Q Werewolf Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.57% | -3.97% | |
| Form 8-K Werewolf Therapeutics, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -3.57% | -3.97% | |
| Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.57% | -3.97% | |
| Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | Press release | GlobeNewswire | -5.18% | -11.32% | |
| Form 8-K Werewolf Therapeutics, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.93% | |
| Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting | Press release | GlobeNewswire | +0.89% | +6.77% | |
| Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | -0.73% | +0.00% | |
| Form 10-Q Werewolf Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -3.65% | |
| Form 8-K Werewolf Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.65% | |
| Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -3.65% | |
| Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit | Press release | GlobeNewswire | +0.00% | -0.93% | |
| Form 8-K Werewolf Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | +4.00% | |
| Werewolf Therapeutics to Participate in the BIO International Convention | Press release | GlobeNewswire | -3.17% | +2.38% | |
| Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -1.61% | +3.23% | |
| HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 | Press release | GlobeNewswire | -5.22% | -6.09% | |
| Form EFFECT Werewolf Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -3.55% | -2.63% | |
| Form 8-K Werewolf Therapeutics, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -3.55% | -2.63% | |
| Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit | Press release | GlobeNewswire | -5.00% | +2.00% | |
| Form 10-Q Werewolf Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.26% | -5.70% | |
| Form 8-K Werewolf Therapeutics, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | -5.70% | |
| Form S-3 Werewolf Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +3.33% | -8.07% | |
| Form S-8 Werewolf Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +3.33% | -8.07% | |
| Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.26% | -5.70% | |
| Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting | Press release | GlobeNewswire | -1.92% | +3.10% | |
| Werewolf Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.92% | +3.10% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HOWL section they belong to.
Where else HOWL is measured.
HOWL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Werewolf Therapeutics, Inc.'s median reaction calculated?
Every labeled HOWL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 345 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 26% of HOWL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HOWL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.